Clinical Trial Update: MB-105 in Patients With CD5 Positive T-cell Lymphoma [Phase 2]

View source ↗

Summary

This update reports a Phase 2 clinical trial of MB-105 for CD5-positive T-cell lymphoma, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Lymphoma

Drugs mentioned

• MB-105

Snippet

Sponsor: March Biosciences Inc | Conditions: Lymphoma, T-Cell | Phase 2 | Status: RECRUITING